Lotus Honoured as One of Asia’s Best Workplaces for the Fifth Consecutive Year

Taipei, Taiwan, 18 August 2026 — Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSE Stock Code: 1795), a leading multinational pharmaceutical company, proudly announces that it has been named a recipient of the HR Asia Best Companies to Work for in Asia 2026 – Taiwan award for the fifth consecutive year. The recognition reflects Lotus’s continued commitment to building a people-focused workplace where employees are heard, supported and empowered to grow.

This year, Lotus was also recognised in three additional HR Asia award categories:

·       HR Asia Diversity, Equity & Inclusion Awards (3rd time winner)

·       HR Asia Sustainable Workplace Awards (2nd time)

·       HR Asia People Transformation Awards (1st time)

These three awards highlight Lotus’s efforts to foster an inclusive culture, strengthen continuous learning and talent development, and support employee wellbeing through responsible and sustainable workplace practices.

“At Lotus, we believe that when employees are heard, supported and given opportunities to grow, they can do their best work and create greater impact,” said Petar Vazharov, Chief Executive Officer of Lotus Pharmaceutical. “Being recognised for the fifth consecutive year, together with these three additional awards, affirms the progress we are making across inclusion, learning and employee wellbeing. We are proud of what our people have built together and will continue to listen, invest and evolve as our organisation grows.”

These honours also follow Alvogen Korea’s recent recognition at the Social Contribution Company Awards for its contributions to environmental sustainability, support for future generations and care for vulnerable communities. Together, these recognitions reflect the values shared across the Lotus Group and its commitment to supporting both employees and the communities in which it operates.

Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness.